➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Harvard Business School

Last Updated: September 30, 2020

DrugPatentWatch Database Preview

Patent: 9,814,784

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,814,784
Title:Antibody-linker-drug conjugate, preparation method therefor, and anticancer drug composition containing same
Abstract: The present invention relates to an antibody-linker-drug conjugate in which an antibody and a cytotoxic drug are conjugated through an enzyme cleavable peptide linker capable of directly binding to a lysine residue of an antibody, a preparation method therefor, and an anticancer drug composition containing the same as an active ingredient.
Inventor(s): Park; Young Jun (Incheon, KR), Jeong; Jin-kyo (Incheon, KR), Choi; Young Mi (Incheon, KR), Lee; Minseob (Incheon, KR), Kim; Yeon Jung (Incheon, KR), Kim; Kyoung Suk (Incheon, KR), Choi; Joon hun (Incheon, KR), Lee; Jin Seo (Incheon, KR), Cho; Eun Joo (Incheon, KR), Song; Hyunnam (Incheon, KR), Park; Sung Jun (Incheon, KR), Lee; Jong-hyoup (Incheon, KR), Lee; Matthew Sangyup (Incheon, KR), Lee; In-Suk (Incheon, KR), Kim; Joon woo (Incheon, KR), Hong; Seung Suh (Incheon, KR)
Assignee: CELLTRION, INC. (Incheon, KR)
Application Number:14/655,357
Patent Claims:see list of patent claims

Details for Patent 9,814,784

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial CELLTRION, INC. (Incheon, KR) 2033-01-03 RX Orphan search
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial CELLTRION, INC. (Incheon, KR) 2033-01-03 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.